


# بِسْمِ اللّٰهِ الرَّحْمٰنِ الرَّحِیْمِ



HOSSAM MAGHRABY



# شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



HOSSAM MAGHRABY

# جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم  
قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
علي هذه الأقراص المدمجة قد أعدت دون أية تغييرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HOSSAM MAGHRABY



بعض الوثائق

الأصلية تالفة



HOSSAM MAGHRABY



بالرسالة صفحات

لم ترد بالأصل



HOSSAM MAGHRABY

# Study of Cyfra 21-1 as A tumor Marker for Cancer Bladder in Egyptian Patients

B ١٢٨.٤

By

*Mohammed Abd El-Aziz Yaseen*  
M.B.B.Ch.



Thesis

Submitted For Partial Fulfillment For The Requirements  
Of **M. Sc. Degree** In *Clinical and chemical Pathology*

Supervisors

Prof. Dr.

*Fetnat Mahmoud Tolba*

*Professor of Clinical Pathology*  
*Benha Faculty of Medicine, Zagazig University*

Prof. Dr.

*Adel Marzouk Agha*

*Assist. Professor of Clinical Pathology*  
*Benha Faculty of Medicine, Zagazig University*

Dr.

*Anas Abd El Rahman Yousef*

*Lecturer of Clinical Pathology*  
*Benha Faculty of Medicine, Zagazig University*

Prof. Dr.

*Mohammed Rasheed Taha*

*Professor of Urology*  
*Faculty of Medicine, Tanta University*

*Benha Faculty of Medicine*  
*Zagazig University*

2002

## *List of Tables*

45	Table (1): Cyfra in normal control and benign control groups.
46	Table (2): Cyfra in normal control and cancer patients.
47	Table (3): Cyfra in benign control and cancer patients groups.
48	Table (4): Cyfra in TCC and SCC groups
49	Table (5): Cyfra in TCC and adenocarcinoma groups.
50	Table (6): Cyfra in SCC and adenocarcinoma groups.
51	Table (7): Cyfra in grade I and grade II groups
52	Table (8): Cyfra in grade I and grade III groups.
53	Table (9): Cyfra in grade II and grade III groups
54	Table (10): Cyfra in patients with benign prostatic hyperplasia and patients with bladder stone.
55	Table (11): Cyfra in patients with kidney stone and patient with bladder stone.
56	Table (12): Cyfra in patients with kidney stone and patient with right ureter stone.
57	Table (13): Correlation between age, Cyfra and grade in cancer patients.

58	Table (14): Correlation between age and Cyfra in benign controls.
59	Table (15): Evaluation parameters of Cyfra cut-off value in differentiating cancer patients from normal controls.
60	Table (16): Evaluation parameters of Cyfra cut-off value in differentiating cancer patients from benign controls.
61	Table (17): Evaluation parameters of Cyfra cut-off value in differentiating cancer patients from normal and benign controls.
62	Table (18): Cancer diagnosed by Cyfra in cancer patients versus normal and benign controls.
63	Table (19): Cancer diagnosed by Cyfra in cancer patients versus normal controls.
64	Table (20): Cancer diagnosed by Cyfra in cancer patients versus benign controls.

### *List of Figures*

Fig. (1): Receiver operating curve figures Cyfra in cancer patient differentiating it from benign and control groups.	64
Figure (2): ROC-curve for Cyfra in cancer patients differentiating it from benign control.	65
Figure (3): ROC curve for Cyfra differentiating it from normal control patient.	66

## *Acknowledgement*

First and foremost thanks to *God*, the most gracious and merciful.

My thanks and deepest appreciation to *Prof. Dr. Fetnat Mahmoud Tolba*, Professor of Clinical Pathology, Benha Faculty of Medicine, Zagazig University for her great advice, guide and time she dedicated during this work.

I'm deeply indebted to *Prof. Dr. Adel Marzouk Agha*, Assist. Professor of Clinical Pathology, Benha Faculty of Medicine, Zagazig University, for his genius Cooperation, wise guidance, valuable instructions, suggestions and encouragement through this work. I fell to him much respect, and I give my wormiest thanks.

I'm deeply grateful to *Dr. Anas Abd El-Rahman Yousef*, Lecturer of Clinical Pathology, Benha Faculty of Medicine, Zagazig University, for his expert direction and efforts in all steps of laboratory work of this study from sampling to interpretation of results.

I wish to express my deepest gratitude and thanks to *Prof. Dr. Mohammed Rasheed Taha*, Professor of Urology, Tanta Faculty of Medicine, Tanta University, for his valuable effort, advice, close observation and follow up of this work.

## Contents

	Page
<b>Introduction and aim of the work .....</b>	<b>1</b>
<b>Review of literature .....</b>	
* Cancer of the bladder .....	3
* Tumor markers .....	17
* Tumor markers of bladder cancer .....	26
* Cyfra 21 – 1 as a new tumor of bladder cancer .....	32
<b>Subjects and Mthods .....</b>	<b>37</b>
<b>Results .....</b>	<b>41</b>
<b>Discussion .....</b>	<b>72</b>
<b>References .....</b>	<b>77</b>
<b>Arabic summary .....</b>	

## Abbreviations

<b>ACTH</b>	<b>Adrenocorticotrophic hormone</b>
<b>ADH</b>	<b>Antidiuretic hormone</b>
<b>BPH</b>	<b>Benign prostatic hyperplasia</b>
<b>BTA</b>	<b>Bard tumor antigen</b>
<b>CIS</b>	<b>Carcinoma insitu</b>
<b>CK</b>	<b>Cytokeratin</b>
<b>CT</b>	<b>Computerized tomography</b>
<b>ELISA</b>	<b>Enzyme linked immunosorbent assay</b>
<b>HCG</b>	<b>Humman chorionic gonadotrophin</b>
<b>NMP 22</b>	<b>Nuclear matrix protein 22</b>
<b>SCC</b>	<b>Squamous cell carcinoma</b>
<b>SD</b>	<b>Standar deviation</b>
<b>SE</b>	<b>Standar error</b>
<b>TCC</b>	<b>Transitonal cell carcinoma</b>
<b>TNM</b>	<b>Tumor, node, metastasis</b>
<b>TUR</b>	<b>Transurethral resection</b>

## *List of Tables*

Table (1): Age and Cyfra in normal control and benign control groups.	47
Table (2): Age and Cyfra in normal control and cancer patients.	48
Table (3): Age and Cyfra in benign control and cancer patients groups.	49
Table (4): Cyfra in TCC and SCC groups	50
Table (5): Cyfra in TCC and adenocarcinoma groups.	51
Table (6): Cyfra in SCC and adenocarcinoma groups.	52
Table (7): Cyfra in grade I and grade II groups	53
Table (8): Cyfra in grade I and grade III groups.	54
Table (9): Cyfra in grade II and grade III groups	55
Table (10): Cyfra in patients with benign prostatic hyperplasia and patients with left kidney stone.	56
Table (11): Cyfra in patients with benign prostatic hyperplasia and patients with bladder stone.	57
Table (12): Cyfra in patients with benign prostatic hyperplasia and patients with right ureter stone.	58
Table (13): Cyfra in patients with left kidney stone and patient with bladder stone.	59
Table (14): Cyfra in patients with left kidney stone and patient with right ureter stone.	60
Table (15): Cyfra in patients with bladder stone and patient with right ureter stone.	61

Table (16): Correlation between age, Cyfra and grade in cancer patients.	62
Table (17): Correlation between age and Cyfra in normal controls.	62
Table (18): Correlation between age and Cyfra in benign controls.	62
Table (19): Evaluation parameters of Cyfra cut-off value in differentiating cancer patients from normal controls.	63
Table (20): Evaluation parameters of Cyfra cut-off value in differentiating cancer patients from benign controls.	64
Table (21): Evaluation parameters of Cyfra cut-off value in differentiating cancer patients from normal and benign controls.	65
Table (22): Cancer diagnosed by Cyfra in cancer patients versus normal and benign controls.	66
Table (23): Cancer diagnosed by Cyfra in cancer patients versus normal controls.	67
Table (24): Cancer diagnosed by Cyfra in cancer patients versus benign controls.	68

### *List of Figures*

Fig. (1): Receiver operating curve figures Cyfra in cancer patient differentiating it from benign and control groups.	69
Figure (2): ROC-curve for Cyfra in cancer patients differentiating it from benign control.	70
Figure (3): ROC curve for Cyfra differentiating it from normal control patient.	71